News|Articles|January 5, 2022

COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of January 5, 2022

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

How many fully vaccinated Americans have received a booster dose?

According to the Centers for Disease Control and Prevention (CDC), as of today, January 5, 2022, at 4:01 PM, EDT, 34.9% of fully vaccinated persons in the US have received a booster dose of COVID-19 vaccine.

How many people in the US have been vaccinated against COVID-19?

According to the CDC as of today, January 4, 2022, at 3:19 PM, EDT:

• 73.9% of total US population has received at least 1 dose
• 62.3% of total US population is fully vaccinated

The 5 states/territories with the highest percentage of population fully vaccinated are:

1. Vermont: 77.8%
2. Puerto Rico: 77.3%
3. Rhode Island:76.9%
4. Maine: 76.1%
5. Connecticut: 75%

How many cases of COVID-19 have been confirmed in the US?

According to the Johns Hopkins COVID-19 interactive map, as of today, January 5, 2022 at 5:21 PM, EDT, there have been:

• 57 528 962 confirmed cases and
• 831 825 deaths

The 5 states with the highest total confirmed cases are:

1. California: 5 782 967
2. Texas: 4 850 849
3. Florida: 4 360 178
4. New York: 3 769 897
5. Illinois: 2 295 438

Deaths: California has the highest number of deaths due to COVID-19 with 76 732 reported fatalities, followed by Texas with 76 130 and Florida with 62 541.

How many cases of COVID-19 have been confirmed globally?

Globally, there have been 297 168 207 confirmed cases, 5 463 916 deaths, and 9 278 252 779 vaccine doses administered.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Latest CME

$(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York$

COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of January 5, 2022

How many fully vaccinated Americans have received a booster dose?

How many people in the US have been vaccinated against COVID-19?

How many cases of COVID-19 have been confirmed in the US?

How many cases of COVID-19 have been confirmed globally?

Related Content

Newer GLP-1 Therapies Linked to Fewer Alcohol-Related Hospitalizations in Adults With AUD

Compulsive Smartphone Use Linked to Depressive Symptoms in Older Adults

ACOG Releases New Guidance on HIV Screening and Prevention

2026 Dyslipidemia Guideline Expands Statin Eligibility to 21.5 Million More US Adults

From Amyloid Clearance to Daytime Function: Why Sleep Quality Matters for Brain Health

Latest CME

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: Preparing for the Emergence of TROP2 ADCs With Immunotherapy in the Earlier Treatment Settings

PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Washington

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Montana/Wyoming

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Burst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 2)

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

24th Annual International Congress on the Future of Breast Cancer® East

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Cross-Disease Integration of Immunotherapy Innovations

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Collaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Pathways to Progress: RAS in GI Cancers (Spotlight CE Session)

Tackling Barriers to Vaccine Uptake: Practical Strategies for Adult Immunization

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Cases and Conversations™: Mineralocorticoid Receptor Antagonists in Patients With HF—Augmenting Current Guidelines with Emerging Evidence

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

IgAN Case Files: Real Conversations, Evolving Evidence

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Montana/Wyoming

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – North Carolina

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Tennessee

Clinical Consultations™: Tailoring Treatment for Cystic Fibrosis (CF) Across Life Stages and Evolving Health Needs

SimulatEd™: Partnering for Precision – A Framework for Personalized Care Planning in Acute Lymphoblastic Leukemia

A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

9th Annual School of Nursing Oncology™

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

MacTel Decoded: Rethinking Conventional Approaches With Novel Neuroprotective Strategies

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Nevada

20th Annual New York Lung Cancers Symposium®

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers